Cytokinetics Sets November 4 for Q3 Earnings Amid Key Drug Filing Plans

  • Cytokinetics to report Q3 2026 results on November 4, 2026, with conference call at 4:30 PM ET.
  • Company plans to submit Supplemental New Drug Application for aficamten in Q4 2026 following positive Phase 3 trial results.
  • Aficamten approved in U.S., China, EU, UK, and Canada for obstructive hypertrophic cardiomyopathy (oHCM).
  • Omecamtiv mecarbil and ulacamten remain investigational for heart failure indications.

Cytokinetics is positioning itself as a leader in cardiovascular therapies, with aficamten's potential expansion into non-obstructive HCM representing a significant growth opportunity. The company's focus on muscle biology innovation aligns with broader industry trends toward targeted treatments for heart failure subtypes. Success in these areas could drive both revenue growth and strategic partnerships.

Regulatory Timing
Whether Cytokinetics can meet its Q4 2026 target for aficamten's Supplemental NDA submission.
Pipeline Progress
The pace at which investigational drugs omecamtiv mecarbil and ulacamten advance through clinical trials.
Commercialization Strategy
How Cytokinetics plans to expand MYQORZO's market reach beyond current approvals.